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Background: Cavopulmonary anastomosis is used for palliation of cyanotic heart
disease. Clinically significant pulmonary arteriovenous malformations occur
in up to 25% of patients after surgical intervention. Cavopulmonary anasto-
mosis creates several modifications to pulmonary physiology that may con-
tribute to the development of pulmonary arteriovenous malformations,
including reduced pulmonary blood flow and the exclusion of inferior vena caval
effluent.
Objective: By comparing the expression of angiogenic and stress-related proteins
after cavopulmonary anastomosis and pulmonary artery banding, we sought to
determine which genes were upregulated independent of reduced pulmonary blood
flow.
Methods: Lambs aged 35 to 45 days were placed into 1 of 3 groups: cavopulmonary
anastomosis (n  6), pulmonary artery banding (n  6), and sham control (n  6)
animals. In our model pulmonary arteriovenous malformations are detectable by
means of bubble-contrast echocardiography 8 weeks after cavopulmonary anasto-
mosis. Lung tissue was harvested for Western blotting at 2 and 5 weeks after
surgery.
Results: Cavopulmonary anastomosis and pulmonary artery banding both in-
creased angiogenic gene expression, but only cavopulmonary anastomosis
induced the expression of endothelial stress-related genes. Vascular endothelial
growth factor was upregulated 2.5-fold after both cavopulmonary anastomosis
(P  .002) and pulmonary artery banding (P  .007). Only cavopulmonary
anastomosis upregulated 2 stress-related genes, HO1 and GLUT1, 2.7-fold
(P  .002) and 3.8-fold (P  .03), respectively. Hypoxia-inducible factor
was upregulated 4-fold (P  .003) after cavopulmonary anastomosis.
Pulmonary artery banding failed to induce the increased expression of any of
these proteins.
Conclusions: Reduced pulmonary blood flow induces a pulmonary angiogenic
response but not an endothelial stress response. These results suggest that oxidative
stress is more relevant to the formation of pulmonary arteriovenous malformations
than angiogenic signaling alone because pulmonary artery banding does not result
in pulmonary arteriovenous malformations. Oxidative stress of the pulmonary
endothelium resulting from cavopulmonary anastomosis may predispose the af-
fected vasculature to arteriovenous shunting.
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Cavopulmonary anastomosis (CPA) is per-formed for the palliation of tricuspid atre-sia and univentricular congenital heart de-fects. This procedure, as originallydescribed by Glenn in 1958, uses an anas-tomosis between the superior vena cava
(SVC) and the right pulmonary artery (RPA) to augment
pulmonary blood flow.1 However, pulmonary arteriovenous
malformations (AVMs) develop in a significant proportion
of patients undergoing CPA. Several series have demon-
strated clinically significant AVMs in up to 25% of patients
after CPA.2,3 Sequelae of these pulmonary AVMs can range
in severity from borderline hypoxemia to progressive cya-
nosis. To study this phenomenon, we have developed an
ovine model that reliably produces pulmonary arteriovenous
shunting 8 weeks after construction of the CPA.
Prior observations have demonstrated widespread pul-
monary vascular remodeling after CPA. Histologic analyses
of lung tissue after CPA reveal the proliferation of dilated
microvascular structures.4,5 Recent findings from this ani-
mal model suggest that inhibited pulmonary angiotensin-
converting enzyme expression and angiotensin II produc-
tion may contribute to the chronic pulmonary vasodilation
after CPA.6
Unfortunately, the physiologic and molecular basis for
this abnormal pulmonary vascular remodeling remains
poorly understood. CPA results in a number of potentially
relevant modifications to the pulmonary circulation. Exclu-
sion of inferior vena caval effluent is likely the most sig-
nificant consequence of CPA. Another major physiologic
alteration caused by CPA is reduced pulmonary blood flow.
In this study we examined the pulmonary expression of
oxidative stress-inducible and angiogenic proteins after
CPA using our ovine model. To exclude changes in gene
expression caused by reduced pulmonary blood flow, we
performed similar analysis on age-matched lambs that un-
derwent pulmonary artery banding (PAB). Because PAB
does not result in the formation of pulmonary AVMs,
changes in patterns of gene expression specific to CPA will
yield valuable insight into the molecular mechanisms re-
sponsible for the development of such malformations.
This study examines the role of hypoxia-inducible factor
1 (HIF-1) in the development of pulmonary arterio-
venous shunting. HIF-1 has been implicated in the patho-
physiology of several pulmonary vascular disorders, includ-
ing pulmonary hypertension.7 HIF-1 upregulates the
expression of numerous genes involved in vascular remod-
eling by binding to a consensus nucleotide sequence known
as the HIF-1-responsive element.8 Some of these genes
include those coding for the oxidative stress-associated fac-
tors hemoxygenase 1 (HO1) and glucose transporter 1
(GLUT1), as well as the angiogenic gene vascular endothe-
lial growth factor (VEGF) and its receptor, Flt-1. This study
examines the early pulmonary expression (at 2 and 5 weeks
after the operation) of these HIF-1-inducible genes, as well
as P-selectin (CD62), an HIF-1-independent marker of
endothelial activation, after CPA and PAB.
Methods
Animal Model
Western sheep, aged 35 to 45 days (n 6), were anesthetized with
isoflurane (2%), intubated, and mechanically ventilated. After me-
dian sternotomy and pericardiotomy, the SVC and RPA were
identified and dissected free from their attachments. The RPA was
divided near the pulmonary bifurcation, and the proximal end was
oversewn (Figure 1). The SVC was similarly divided at the
cavoatrial junction, and the atrial end was oversewn. Intravenous
heparin was administered (300 U/kg), and 16F to 20F venous
cannulas were placed to bypass the SVC to the right atrium. The
SVC was then anastomosed to the RPA in an end-to-end fashion
with running polypropylene sutures. The venous cannulas were
removed, and the sternum was closed. After skin closure, the
lambs were extubated and allowed to recover.
Another set of age-matched lambs underwent PAB (n  6).
After sternotomy, the left pulmonary artery (LPA) was dissected
free from its attachments. The LPA was then encircled with
umbilical tape, and an ultrasonic flow probe (Transonic Systems,
Inc, Ithaca, NY) was placed. Once baseline flow measurements
were recorded, the umbilical tape was tightened around the LPA
with surgical clips to reduce flow to 20% of baseline values. The
band was then further secured by 5-0 polypropylene sutures placed
in the adventitia of the LPA.
A third group of lambs of the same age served as sham-
operated control animals (n  6). The preparation and dissection
was the same as that described for the Glenn cohort. The RPA was
occluded with a vascular clamp for 30 minutes. After this time, the
clamp was removed, and the chest was closed as described above.
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care,” formulated by the Na-
tional Society of Medical Research, and the “Guide for the Care
and Use of Laboratory Animals,” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996. The
protocol was approved by the Committee on Animal Research at
the University of California, San Francisco.
Echocardiography
Pulmonary AV shunting was demonstrated by means of bubble
contrast echocardiography. Epicardial echocardiography was per-
formed on each animal after median sternotomy. In the CPA
cohort 5 mL of a saline solution–blood mixture was agitated to
produce bubbles and then injected sequentially into the SVC and
inferior vena cava. In the PAB group a similar bubbled saline
solution–blood mixture was injected into each pulmonary artery
sequentially. The appearance of bubbles in the left atrium within 5
cardiac cycles after SVC injection indicates AV shunting.9
Tissue Harvest
Lambs were killed at 2 and 5 weeks after the operation to obtain
tissue for analysis. Animals were intubated and mechanically
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ventilated. After median sternotomy, the lambs were anticoagu-
lated with sodium heparin (300 U/kg). The lambs were then put to
death with an infusion of sodium pentobarbital, the lungs were
removed, and samples were snap-frozen in liquid nitrogen.
Western Blot Analysis
Specimens of right lung tissue from CPA and control groups and
left lung tissue from the PAB cohort were obtained as described
above. Specimens were homogenized, and proteins were extracted
as previously described.10 Proteins were then transferred to a
polyvinylidene difluoride membrane (Amersham Pharmacia Bio-
tech Inc, Piscataway, NJ). The membrane was soaked in Tris-
buffered saline solution (100 mM Tris-HCl pH 7.5 and 150 mM
NaCl) containing 5% nonfat powdered milk and 0.1% Tween-20 to
block nonspecific binding. The membrane was then incubated
overnight at 4°C with the following primary antisera at the spec-
ified dilutions: HIF-1, 1:1000 (BD Transduction Laboratories,
Lexington, Ky); VEGF, 1:200 (Santa Cruz Biotechnology, Santa
Cruz, Calif); GLUT-1, 1:200 (Flt, Santa Cruz Biotechnology);
HO-1, 1:200 (Santa Cruz Biotechnology); and CD62, 1:200 (Re-
search Diagnostics, Inc, Flanders, NJ). Blots were washed and
incubated for 30 minutes at 4°C with a peroxidase-conjugated
secondary antibody (1:20,000 dilution, Vector Laboratories, Inc,
Burlingame, Calif). Immunoreactivity was detected with the Su-
persignal chemiluminescent substrate kit (Pierce Chemical Com-
pany, Rockford, Ill). Quantitative assessment of band densities was
performed by using scanning densitometry (1D Image Analysis
Software; Eastman Kodak Company, Rochester, NY).
Immunohistochemistry
Immunolocalization was performed as previously described.9 In
brief, lung tissue from experimental and control animals at 5 weeks
after CPA, PAB, or sham surgery was fixed in Histochoice (Am-
resco, Inc, Solon, Ohio). Tissue was then paraffin embedded,
sectioned at 7 m, and mounted onto glass slides. Slides were
deparaffinized by means of immersion for 6 minutes each in
xylene and 100%, 95%, 70%, and 50% ethanol. Slides were
washed with Tris-buffered saline solution (50 mmol/L, pH 7.6)
and then incubated with 0.5% hydrogen peroxidase with 1 mg/mL
of saponin for 30 minutes to quench endogenous peroxidases.
Sections were incubated with 4% serum from the host species for
the secondary antisera to reduce nonspecific antibody binding.
Sections were incubated for 18 hours with a 1:200 dilution of
either the CD62 or VEGF primary antisera described above. Vi-
sualization of staining was accomplished with the Vectastain elite
kit (Vector Laboratories), with diaminobenzidine as the chromo-
gen (DAB kit, Zymed Laboratories, San Francisco, Calif).
Statistical Analysis
Data were analyzed with Statview, a commercially available soft-
ware package (SAS Institute, Inc, Cary, NC). Protein analysis was
evaluated with 3 animals at both 2 and 5 weeks in the CPA, PAB,
and sham groups for a total of 6 animals in each cohort. Figures
include representative Western blot results for each experimental
group. Analysis of statistical differences between groups at each
time point was performed by means of paired, 2-tailed Student t
tests. Significant differences between the experimental and control
groups were confirmed by means of analysis of variance. All
values are expressed as means  SD.
Results
Detection of Pulmonary Arteriovenous Shunting
Contrast echocardiography detected arteriovenous shunting
in all animals evaluated 8 weeks or later (n 23) after CPA.
Arteriovenous shunting was absent in the PAB lambs 12
weeks after surgical intervention (n  3). No shunting was
detected in any animals studied after sham surgery. Atrial or
Figure 1. CPA as performed in this model.
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ventricular septal defects were not present in any of the
animals.
HIF-1 Protein Expression After CPA and PAB
HIF-1 was upregulated in lung tissue 4.3 0.10-fold (P
.001) at 2 weeks and increased 3.9  0.16-fold at 5 weeks
(P  .003) after CPA. PAB failed to induce increased
HIF-1 protein expression at either 2 or 5 weeks after
surgical intervention (P  .2, Figure 2).
Stress-related Gene Expression Was Induced by CPA
but not by PAB
Expression of HO-1 and GLUT-1 protein was increased
after CPA but not after PAB. HO-1 protein expression was
increased 3.3  0.10-fold at 2 weeks (P  .002) and 2.3 
0.03-fold at 5 weeks (P  .001) after CPA (Figure 3). CPA
caused a 2.5  0.25-fold increase in GLUT-1 expression at
2 weeks (P .02) and a 4.9 0.58-fold increase at 5 weeks
(P  .03) after the operation (Figure 4). PAB did not result
in a statistically significant increase in the expression of
HO-1 or GLUT-1 at either time point (P  .2).
CD62 Expression Was Induced Only After CPA
CPA caused a marked increase in the expression of CD62,
a marker of endothelial activation. There was a 4.6 
0.1-fold increase at 2 weeks (P  .002) and a 3.6 
0.02-fold increase at 5 weeks in CD62 expression (P 
.001). CD62 expression was unchanged at both 2 and 5
weeks after PAB (P  .2) (Figure 5).
CPA and PAB Both Cause Enhanced Pulmonary
Angiogenic Signaling
Pulmonary expression of VEGF and Flt-1, a VEGF recep-
tor, were enhanced after both procedures. VEGF expression
was increased 4.9  0.36-fold in CPA specimens (P 
.002) and 3.7  0.52-fold in PAB specimens (P  .004) at
2 weeks. At 5 weeks, expression of VEGF protein was
upregulated 3.5  0.16-fold after CPA (P  .003) and
Figure 2. Pulmonary HIF-1 protein expression after CPA and
PAB. Representative results from Western blot analysis are dis-
played with corresponding densitometry results. Expression in-
creased 4-fold after CPA and was unchanged after PAB. Data are
expressed as means  SD (n  3 at each time point).
Figure 3. HO-1 protein expression was upregulated 2.5-fold after
CPA (P  .002) and unchanged after PAB. Representative results
from Western blot analysis are displayed with corresponding
densitometry results. Data are expressed as means  SD (n  3
at each time point).
Figure 4. Pulmonary GLUT-1 expression was upregulated 2.5-fold
after CPA (P  .02) but was unchanged after PAB. Representative
results from Western blot analysis are displayed with corre-
sponding densitometry results. Data are expressed as means 
SD (n  3 at each time point).
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3.2  0.26-fold after PAB (P  .01, Figure 6). Pulmonary
flt-1 protein expression was upregulated 2.5  0.28-fold in
CPA specimens (P  .02) and 2.1  0.26-fold in PAB
specimens (P  .03) 2 weeks after the operation. At 5
weeks, flt-1 expression was increased 3.4  0.19-fold after
CPA (P  .006) and 3.5  0.21-fold after PAB (P  .006,
Figure 7).
Immunolocalization of VEGF to Pulmonary
Vasculature
At 5 weeks, immunohistochemistry of lung sections re-
vealed that CPA and PAB both enhanced endothelial stain-
ing of VEGF when compared with the sham control spec-
imens (Figure 8). In the control specimens pulmonary
VEGF staining was not remarkable in comparison with
background levels.
Immunolocalization of P-Selectin/CD62 to Pulmonary
Vasculature
Marked CD62 staining of pulmonary arterial endothelium
was present at 5 weeks after CPA but was absent in both the
PAB and control sections (Figure 9). Time-matched control
specimens demonstrated only minimal staining of the pul-
monary microvascular endothelium.
Discussion
The development of pulmonary AVMs after CPA can have
disastrous consequences for the child with cyanotic heart
disease, leading to further hemodynamic decompensation
and, ultimately, death. The cause of the pulmonary vascular
remodeling in this setting is still unknown.
Our results suggest that CPA causes oxidant stress within
the pulmonary vasculature. CPA markedly increases the
expression of the stress-associated factors, including HIF-
1. Moreover, this phenomenon is not limited to a HIF-1-
specific pathway because CD62 is also upregulated. En-
hanced oxidative stress-related signaling was independent
of reduced pulmonary blood flow because PAB failed to
cause increased expression of any of these genes.
Interestingly, enhanced angiogenic signaling may not
Figure 7. Pulmonary Flt-1 protein expression was increased 2- to
3-fold after CPA (P  .006) and PAB (P  .01). Representative
results from Western blot analysis are displayed with corre-
sponding densitometry results. Data are expressed as means 
SD (n  3 at each time point).
Figure 5. Pulmonary CD62 protein expression was upregulated 3-
to 4-fold after CPA (P  .002) and unchanged after PAB. Repre-
sentative results from Western blot analysis are displayed with
corresponding densitometry results. Data are expressed as
means  SD (n  3 at each time point).
Figure 6. Pulmonary VEGF protein expression was upregulated 3-
to 4-fold after both CPA (P  .003) and PAB (P  .008). Repre-
sentative results from Western blot analysis are displayed with
corresponding densitometry results. Data are expressed as
means  SD (n  3 at each time point).
Malhotra et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 3 483
CH
D
play a central role in the formation of pulmonary AVMs
because CPA and PAB both increase the expression of
VEGF and Flt-1. The early appearance of increased sub-
pleural vascular markings after CPA led us to initially
suspect the involvement of an angiogenic stimulus in the
development of these AVMs. However, we found the same
degree of enhanced subpleural vascularity in the lungs of
the sheep that underwent PAB. Yet we found no evidence of
formation pulmonary AVMs after PAB in this animal
model. Presumably, reduced pulmonary blood flow is the
stimulus for the increased expression of these angiogenic
factors.
The altered physiology resulting from CPA may cause a
change in the redox state of the pulmonary vascular bed.
Exclusion of inferior venous drainage from the pulmonary
circulation could potentially interrupt the delivery of a me-
diator of normal vascular development derived from the
liver or some other lower body source. This theory is
supported by reports of resolution of pulmonary AVMs
after the inclusion of inferior venous blood.11,12 Pulmonary
endothelial oxidative stress may result from the lack of this
putative protective factor and serve as a stimulus for the
pathologic vascular remodeling responsible for arterio-
venous shunting. Further work is warranted to fully under-
stand the mechanisms involved in formation of pulmonary
AVMs after CPA.
We thank Mario Trujillo and Sam Suleman for their technical
assistance.
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Discussion
Dr Yasunaru Kawashima (Osaka, Japan). As one of the
criminals of producing pulmonary AVMs by advocating the total
cavopulmonary shunt operation, I am very much grateful to the
authors for investigating the reasons for pulmonary AVMs. I
understand, from your presentation, that you have shown that
CPA, rather than PAB, upregulated the oxidative stress. I wonder
how you can imagine that the oxidative stress may predispose the
affected vasculature to arteriovenous shunting.
It is my question whether the oxidative stress in patients with
well-developed AVM will upregulate the oxidative stress. Another
question is whether you think that the upregulated oxidative stress
is a fundamental factor in addition to the lack of some substances
delivered from the liver and perfused into the lung in development
of pulmonary AVMs.
Dr Malhotra. To the first question, oxidative stress probably
affects various endothelium-dependent vasodilation mechanisms
and probably inhibits regulation of normal vascular tone. I believe
it does create a substrate, perhaps for the development of pulmo-
nary AVMs. Unfortunately, I think we still have much work to do
on this topic.
Dr Frank Sellke (Boston, Mass). Your hypothesis is that there
is a differential expression of these growth factors, such as HIF-
1, and that this is based on oxidative stress. You can measure
oxidative stress in the different lung segments. That would really
pin down your hypothesis. Have you done that or are you consid-
ering doing that?
Dr Malhotra. We have not done that at this time, but that
would be an interesting investigation to pursue.
Dr Sellke. Also, I believe you showed that expression of VEGF
was increased in the vessel, as opposed to the surrounding tissue.
Dr Malhotra. We have had localization to the endothelium,
yes.
Dr Sellke. The VEGF receptors are localized to the endothe-
lium, but VEGF expression is usually increased everywhere. I
think that is true in the lung, in the heart, and in skeletal muscle.
I am surprised that the expression in your study was localized to
the vessel wall. Is that what you found?
Dr Malhotra. Right, that the protein is increased in the vessel
wall.
Dr Christian Pizarro (Orlando, Fla). If these animals, after
you created the model, were noncyanotic, how do you put together
the fact that HIF was induced when I would take it that the
saturations were over 90%?
Second, did you look at EGR-1 and the theory that early growth
factor is supposed to be induced as rapidly as HIF-1 in patients
who have this type of model created?
Third, did you look at different isoforms of VEGF, meaning the
short versus the long forms? We know that they are located and
express differently, and perhaps you could have looked at some of
that.
Dr Malhotra. To explain upregulation of HIF, we do not
postulate that it is a hypoxic environment. These lambs were
normal healthy lambs that underwent CPA. We do, however,
believe that HIF is a detector of redox status in the parenchyma,
and the redox status may be altered by the lack of this hepatic
factor.
Second, in response to early growth factor, we have just begun
to look at that, and therefore that is a very timely point.
In terms of the isoforms, we have only looked at VEGF-165.
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